Attempting to make money from misery is miserable, positively swinish. But someone’s got to do it. And directing capital to drug makers who aim to profit by alleviating misery makes me feel better, which I could use after my common cold caused me to find every bunker at Dyker Beach yesterday. At least that’s my story for shooting 106 and I’m sticking to it.
How many of us have been able to survive and reproduce, have stellar careers in the arts, sciences, professions and hamburger flipping because of a mold called penicillin?
Now, my stellar career has been more white dwarfish than super nova, so I hesitate to offer ideas to all but the intrepid sailor willing to test his balsa wood Kon-Tiki against the mighty Pacific. But just as I know my next approach shot will hit the green next week, I know there are people brainier than I attacking the H1N1 influenza and they could be right -- saving lives and enriching investors.
Kev (yes, in his megalomaniacal certainty that it’s all about Kev, he is referring to himself in the third person) is adding Novavax (NVAX) to the portfolio at $2.03. This Rockville, Md., company reported encouraging results from its virus-like particle (VLP) vaccine in mice and ferrets dosed with the 1918 Spanish flu virus.
I’m no scientist or lover of rodents, and this is obviously a speculative roll of the dice that only the lonely should play, but I’m buying into it for now.
PALM, F, AMD, DDR remain as well. This is no bear market rally. Obama’s competence becomes more evident every day, and markets are responding.
Don't know much about the NBA, but Bulls-Celtics series is terrific. Derrick Rose sunk me in last year's NCAA championship game. Maybe he'll make up for it in Boston tomorrow like he did last night in Chicago. The Bulls will win outright.
Meanwhile, taking Dunkirk in the Kentucky Derby tomorrow. Hopefully, some horse’s behind (there are a bunch of them) won’t get in his way.
No comments:
Post a Comment